Published on: February 21, 2014

SAAS contract win

Instem has announced a useful SaaS contract, which will see the group deliver a third-party software product into a top 10 global pharma group (unnamed). Revenues are $200,000 per annum, and margin will be modest given the third-party nature of the product, but this represents a step forward in SaaS revenue and highlights Instem’s position as chosen provider to big pharma. We make no changes to estimates but take comfort from this news.

Related Content